Boston Trust Walden Corp Has $7.55 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Boston Trust Walden Corp lowered its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 15,361 shares of the medical equipment provider’s stock after selling 1,581 shares during the period. Boston Trust Walden Corp’s holdings in Intuitive Surgical were worth $7,546,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Creekmur Asset Management LLC increased its stake in shares of Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. Ridgewood Investments LLC acquired a new stake in Intuitive Surgical in the second quarter worth $26,000. Delos Wealth Advisors LLC increased its stake in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares in the last quarter. Godsey & Gibb Inc. raised its holdings in shares of Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares during the period. Finally, LRI Investments LLC bought a new position in shares of Intuitive Surgical during the 1st quarter worth about $30,000. 83.64% of the stock is currently owned by institutional investors.

Insider Transactions at Intuitive Surgical

In related news, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the sale, the director now directly owns 821 shares in the company, valued at approximately $402,519.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 52,192 shares of company stock worth $25,398,571 in the last quarter. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $511.27 on Friday. The firm has a market cap of $182.10 billion, a price-to-earnings ratio of 82.20, a P/E/G ratio of 5.11 and a beta of 1.39. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $523.34. The firm’s 50-day simple moving average is $487.98 and its two-hundred day simple moving average is $442.67.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ISRG shares. Barclays upped their price target on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Royal Bank of Canada upped their target price on Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research report on Friday, October 18th. JPMorgan Chase & Co. lifted their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Evercore ISI restated a “cautious” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, Piper Sandler reiterated an “overweight” rating and set a $538.00 price objective (up from $495.00) on shares of Intuitive Surgical in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus price target of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.